| Literature DB >> 29276236 |
Abstract
Rheumatoid arthritis (RA) is a disease where the immune system attacks the linings of the joints, resulting in joint pain, stiffness, swelling, and destruction. Although many products are available for the treatment of RA, limitations such as adverse reactions and tolerance greatly affect adherence. Many of the current biologic disease-modifying antirheumatic drugs on the market are injectables, leaving a void to be filled for a product that can be taken orally. The most advanced of these approaches, the Janus kinase (JAK) inhibitors, are oral drugs that have not only made a breakthrough in RA, but also other skin conditions.Entities:
Keywords: formulary management/P&T; intravenous therapy; rheumatology
Year: 2017 PMID: 29276236 PMCID: PMC5735748 DOI: 10.1177/0018578717729668
Source DB: PubMed Journal: Hosp Pharm ISSN: 0018-5787